OperaV1, Main, Exploration, bibRecord, 000A69

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Identifieur interne : 000A69 ( Main/Exploration ); précédent : 000A68; suivant : 000A70

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Auteurs : Michael Manns [Allemagne] ; Henk Reesink ; Thomas Berg ; Geoffrey Dusheiko ; Robert Flisiak ; Patrick Marcellin ; Christophe Moreno ; Oliver Lenz ; Paul Meyvisch ; Monika Peeters ; Vanitha Sekar ; Kenneth Simmen ; Rene Verloes

Source :

Antiviral therapy ; 2011.

RBID : pubmed:22024518

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Bilirubin (analysis), Double-Blind Method, Drug Therapy, Combination, Female, Genotype, Hepacivirus (drug effects), Hepatitis C (drug therapy), Hepatitis C (virology), Heterocyclic Compounds, 3-Ring (administration & dosage), Heterocyclic Compounds, 3-Ring (adverse effects), Heterocyclic Compounds, 3-Ring (therapeutic use), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (therapeutic use), Male, Middle Aged, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (therapeutic use), Protease Inhibitors (administration & dosage), Protease Inhibitors (adverse effects), Protease Inhibitors (therapeutic use), RNA, Viral (blood), Recombinant Proteins (administration & dosage), Recombinant Proteins (therapeutic use), Ribavirin (administration & dosage), Ribavirin (pharmacology), Ribavirin (therapeutic use), Simeprevir, Sulfonamides (administration & dosage), Sulfonamides (adverse effects), Sulfonamides (therapeutic use), Viral Load.
MESH :
- chemical , administration & dosage : Antiviral Agents, Heterocyclic Compounds, 3-Ring, Interferon-alpha, Polyethylene Glycols, Protease Inhibitors, Recombinant Proteins, Ribavirin, Sulfonamides.
- chemical , adverse effects : Antiviral Agents, Heterocyclic Compounds, 3-Ring, Protease Inhibitors, Sulfonamides.
- chemical , analysis : Bilirubin.
- chemical , blood : RNA, Viral.
- chemical , pharmacology : Ribavirin.
- chemical , therapeutic use : Antiviral Agents, Heterocyclic Compounds, 3-Ring, Interferon-alpha, Polyethylene Glycols, Protease Inhibitors, Recombinant Proteins, Ribavirin, Sulfonamides.
- drug effects : Hepacivirus.
- drug therapy : Hepatitis C.
- virology : Hepatitis C.
- Adolescent, Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Genotype, Humans, Male, Middle Aged, Simeprevir, Viral Load.

Abstract

Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients.

DOI: 10.3851/IMP1894
PubMed: 22024518

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.</title>
<author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. manns.michael@mh-hannover.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
</author>
<author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
</author>
<author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
</author>
<author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
</author>
<author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
</author>
<author><name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
</author>
<author><name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
</author>
<author><name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
</author>
<author><name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
</author>
<author><name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="doi">10.3851/IMP1894</idno>
<idno type="RBID">pubmed:22024518</idno>
<idno type="pmid">22024518</idno>
<idno type="wicri:Area/PubMed/Corpus">000298</idno>
<idno type="wicri:Area/PubMed/Curation">000298</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000304</idno>
<idno type="wicri:Area/Ncbi/Merge">000913</idno>
<idno type="wicri:Area/Ncbi/Curation">000913</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000913</idno>
<idno type="wicri:Area/Main/Merge">000A69</idno>
<idno type="wicri:Area/Main/Curation">000A69</idno>
<idno type="wicri:Area/Main/Exploration">000A69</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.</title>
<author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. manns.michael@mh-hannover.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
</author>
<author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
</author>
<author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
</author>
<author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
</author>
<author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
</author>
<author><name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
</author>
<author><name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
</author>
<author><name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
</author>
<author><name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
</author>
<author><name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
</author>
</analytic>
<series><title level="j">Antiviral therapy</title>
<idno type="e-ISSN">2040-2058</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Bilirubin (analysis)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Genotype</term>
<term>Hepacivirus (drug effects)</term>
<term>Hepatitis C (drug therapy)</term>
<term>Hepatitis C (virology)</term>
<term>Heterocyclic Compounds, 3-Ring (administration & dosage)</term>
<term>Heterocyclic Compounds, 3-Ring (adverse effects)</term>
<term>Heterocyclic Compounds, 3-Ring (therapeutic use)</term>
<term>Humans</term>
<term>Interferon-alpha (administration & dosage)</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Polyethylene Glycols (administration & dosage)</term>
<term>Polyethylene Glycols (therapeutic use)</term>
<term>Protease Inhibitors (administration & dosage)</term>
<term>Protease Inhibitors (adverse effects)</term>
<term>Protease Inhibitors (therapeutic use)</term>
<term>RNA, Viral (blood)</term>
<term>Recombinant Proteins (administration & dosage)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Ribavirin (administration & dosage)</term>
<term>Ribavirin (pharmacology)</term>
<term>Ribavirin (therapeutic use)</term>
<term>Simeprevir</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (adverse effects)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Heterocyclic Compounds, 3-Ring</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Protease Inhibitors</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
<term>Heterocyclic Compounds, 3-Ring</term>
<term>Protease Inhibitors</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Bilirubin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Heterocyclic Compounds, 3-Ring</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Protease Inhibitors</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Simeprevir</term>
<term>Viral Load</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Basse-Saxe</li>
</region>
<settlement><li>Hanovre</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
<name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
<name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
<name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
<name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
<name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
<name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
<name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
<name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
<name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
<name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
<name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
</noCountry>
<country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A69 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A69 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22024518
   |texte=   Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22024518" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024

Serveur d'exploration sur l'opéra

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.